A Phase 2 interventional study of VX-147 in Glomerulosclerosis, Focal Segmental, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 44 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 40th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2020, is one of 29 in phase 2, and was the 44th registered.
106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.
Browse Glomerulosclerosis, Focal Segmental studies →18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 34 more countries
Ages 12+
Akebia Therapeutics · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, Germany, Italy and 2 more countries
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 31 · Phase 3 5 · Phase 4 4
First in 1996; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.
Median enrollment 30 across the 56 interventional studies, 252 across the 13 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 3 studies filed under Glomerulosclerosis, Focal Segmental — fewer than ten, so there is no comparison to draw.
10 of the studies in Glomerulosclerosis, Focal Segmental with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01094327University of MiamiProteinuria in Pre and Post Transplant | 2026-11-30 |
| NCT06500702SanofiA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | 2026-12-23 |
| NCT07219121Travere Therapeutics, Inc.Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | 2027-03 |
| NCT05583942Northwell HealthA Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) | 2027-03-01 |
| NCT05588063Northwell HealthtaVNS for FRNS in Children | 2027-03-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (\<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and \<2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.
Drug: VX-147
Tablets for oral administration.
Also known as: IXP
Percent Change From Baseline in UPCR
Time frame: From Baseline up to Week 13
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline up to Week 17
Maximum Observed Concentration (Cmax) of VX-147
Time frame: Pre-dose and at 0.25, 0.5, 1, 2, 4, and 12 hours post-dose on Day 1 and Week 5
Observed Pre-dose Concentration (Ctrough) of VX-147
Time frame: Pre-dose on Day 8, 15, Week 3, 5, 9 and 13
Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147
Time frame: Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5
This study was planned in 2 parts: Part A (Treatment Period), which consisted of 2 cohorts (i.e., cohort 1 and 2) and Part B (Optional Exploratory Off-treatment Follow-up Period). The primary and secondary efficacy analyses and safety analyses were planned for only Part A.
| Milestone | VX-147 |
|---|---|
| Started | 16 |
| Cohort 1 | 3 |
| Cohort 2 | 13 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Withdrawal of consent (not due to adverse event) | 1 |
| percent change | VX-147 |
|---|---|
| Cohort 1 | -47.7 (-70.1 to -8.5) |
| Cohort 2 | -47.5 (-63.4 to -24.6) |
| Total | -47.6 (-60.0 to -31.3) |
| Participants | VX-147 |
|---|---|
| Cohort 1: Participants With TEAEs | 3 |
| Cohort 1: Participants With SAEs | 0 |
| Cohort 2: Participants With TEAEs | 12 |
| Cohort 2: Participants With SAEs | 1 |
| micrograms per milliliter (mcg/ml) | VX-147 |
|---|---|
| 15 mg qd: Day 1 | 0.168 ± 0.0630 |
| 45 mg qd: Week 5 | 0.846 ± 0.303 |
| mcg/ml | VX-147 |
|---|---|
| 15 mg qd: Day 8 | 0.153 ± 0.0984 |
| 15 mg qd: Day 15 | 0.123 ± 0.0796 |
| 45 mg qd: Week 3 | 0.379 ± 0.249 |
| 45 mg qd: Week 5 | 0.492 ± 0.265 |
| 45 mg qd: Week 9 | 0.446 ± 0.342 |
| 45 mg qd: Week 13 | 0.529 ± 0.302 |
| hour*mcg/mL (h*mcg/mL) | VX-147 |
|---|---|
| Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147 | 15.3 ± 6.37 |
Collected over Day 1 up to Week 17. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VX-147 : Cohort 1 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| VX-147: Cohort 2 | 0/13 (0%) | 1/13 (7.7%) | 12/13 (92.3%) |
| VX-147 Total | 0/16 (0%) | 1/16 (6.3%) | 15/16 (93.8%) |
| Event | VX-147 : Cohort 1 | VX-147: Cohort 2 | VX-147 Total |
|---|---|---|---|
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/13 | 1/16 |
| Deep vein thrombosisVascular disorders | 0/3 | 1/13 | 1/16 |
| Event | VX-147 : Cohort 1 | VX-147: Cohort 2 | VX-147 Total |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/3 | 0/13 | 1/16 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 1/13 | 2/16 |
| NauseaGastrointestinal disorders | 1/3 | 2/13 | 3/16 |
| VomitingGastrointestinal disorders | 1/3 | 0/13 | 1/16 |
| Tinea pedisInfections and infestations | 1/3 | 0/13 | 1/16 |
| Electrocardiogram ST segment depressionInvestigations | 1/3 | 0/13 | 1/16 |
| HeadacheNervous system disorders | 1/3 | 3/13 | 4/16 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/13 | 1/16 |
| Decubitus ulcerSkin and subcutaneous tissue disorders | 1/3 | 0/13 | 1/16 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 3/13 | 3/16 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Continuous(years) | VX-147 |
|---|---|
| Cohort 1 | 45.0 ± 10.5 |
| Cohort 2 | 37.3 ± 15.2 |
| Sex: Female, Male(Participants) | VX-147 |
|---|---|
| Cohort 1 — Female | 2 |
| Cohort 1 — Male | 1 |
| Cohort 2 — Female | 7 |
| Cohort 2 — Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | VX-147 |
|---|---|
| Cohort 1 — Hispanic or Latino | 0 |
| Cohort 1 — Not Hispanic or Latino | 3 |
| Cohort 1 — Unknown or Not Reported | 0 |
| Cohort 2 — Hispanic or Latino | 0 |
| Cohort 2 — Not Hispanic or Latino | 13 |
| Cohort 2 — Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | VX-147 |
|---|---|
| Cohort 1 — American Indian or Alaska Native | 0 |
| Cohort 1 — Asian | 0 |
| Cohort 1 — Native Hawaiian or Other Pacific Islander | 0 |
| Cohort 1 — Black or African American | 3 |
| Cohort 1 — White | 0 |
| Cohort 1 — More than one race | 0 |
| Cohort 1 — Unknown or Not Reported | 0 |
| Cohort 2 — American Indian or Alaska Native | 0 |
| Cohort 2 — Asian | 0 |
| Cohort 2 — Native Hawaiian or Other Pacific Islander | 0 |
| Cohort 2 — Black or African American | 13 |
| Cohort 2 — White | 0 |
| Cohort 2 — More than one race | 0 |
| Cohort 2 — Unknown or Not Reported | 0 |
| Urine Protein to Creatinine Ratio (UPCR)(g/g) | VX-147 |
|---|---|
| Cohort 1 | 3.47 ± 1.07 |
| Cohort 2 | 1.77 ± 0.49 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.
Ran from Jun 2020 to primary completion in Nov 2021, 17 months.
Results were first posted in Jul 2023, 1 year 7 months after primary completion. A results delay was requested in Nov 2022.
Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inaxaplin
Glomerulosclerosis, Focal Segmental →
Vertex Pharmaceuticals Incorporated →